Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma

被引：0
|
作者：
Peng Yuan
Jinhua Song
Fei Wang
Guangyu Zhu
Baoan Chen
机构：
[1] Zhongda Hospital,Department of Hematology and Oncology (Key Discipline of Jiangsu Medicine), Medical School
[2] Southeast University,Hepatobiliary Center
[3] The First Affiliated Hospital of Nanjing Medical University,Department of Interventional Radiology, Medical School
[4] Zhongda Hospital,undefined
[5] Southeast University,undefined
来源：
Investigational New Drugs | 2022年 / 40卷
关键词：
Intrahepatic cholangiocarcinoma; Conversion therapy; TACE; lenvatinib; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1125 / 1132
页数：7
相关论文
共 50 条
  • [21] ASO Author Reflections: Intrahepatic Cholangiocarcinoma: Downstaging Strategies Open the Gate to Surgery and Cure
    Karim Boudjema
    Julien Edeline
    [J]. Annals of Surgical Oncology, 2020, 27 : 3738 - 3739
  • [22] Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma
    Cho, Yeona
    Kim, Tae Hyung
    Seong, Jinsil
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 (08) : 620 - 629
  • [23] Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
    Zhao, Rongce
    Zhou, Jing
    Li, Shaohua
    Wei, Wei
    Guo, Rongping
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
    Zhao, Rongce
    Zhou, Jing
    Miao, Zhaoxia
    Xiong, Xinhao
    Wei, Wei
    Li, Shaohua
    Guo, Rongping
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [25] Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma.
    Shi, Guo-Ming
    Jian, Zhou
    Fan, Jia
    Huang, Xiao-Yong
    Wu, Dong
    Liang, Fei
    Lu, Jia-Cheng
    Yang, Guo-Huan
    Chen, Yi
    Ge, Ning-Ling
    Ji, Yuan
    Hou, Y. Y.
    Sun, Hui-Chuan
    Qiu, Shuang-Jian
    Ye, Qing-Hai
    Huang, Xiao-Wu
    Shi, Ying-Hong
    Gao, Qiang
    Yang, Xin-Rong
    Wang, Zheng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative option for advanced unresectable intrahepatic cholangiocarcinoma: a retrospective real-world study
    Dong, Zhitao
    Sui, Chengjun
    Lu, Jiongjiong
    Guo, Junwu
    Duan, Kecai
    Wang, Kui
    Geng, Li
    Dai, Binghua
    Yang, Jiamei
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [27] Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of This Novel Treatment Option
    Akshat Saxena
    Lourens Bester
    Terence C. Chua
    Francis C. Chu
    David L. Morris
    [J]. Annals of Surgical Oncology, 2010, 17 : 484 - 491
  • [28] Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of This Novel Treatment Option
    Saxena, Akshat
    Bester, Lourens
    Chua, Terence C.
    Chu, Francis C.
    Morris, David L.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (02) : 484 - 491
  • [29] Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A preliminary assessment of this novel treatment option
    Saxena, A.
    Bester, L.
    Chua, T. C.
    Morris, D. L.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S103 - S103
  • [30] Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study
    Li, Xingzhi
    Wang, Xiaobo
    Bai, Tao
    Chen, Jie
    Lu, Shaolong
    Wei, Tao
    Tang, Zhihong
    Zhao, Guilin
    Lu, Huaze
    Li, Lequn
    Wu, Feixiang
    [J]. DIGESTIVE AND LIVER DISEASE, 2024, 56 (06) : 1078 - 1086
12345